ST. MARYS, W. Va.--(BUSINESS WIRE)--ProtoKinetix, Incorporated (OTC: PKTX) (the "Company" or "ProtoKinetix") (www.protokinetix.com) today announced the start of a Phase 1 first-in-human clinical trial ...
Diabetes mellitus (DM) is a metabolic disease characterized by pancreatic malfunction and poor production of insulin. Imagine your pancreas is a factory for insulin, a key hormone that keeps your ...
Wenzhou Medical University researchers have reimagined the spleen as a viable site for islet transplantation, enabling long-term diabetes control without the burden of full immunosuppression.
Researchers have developed a vascularized organoid model of hormone secreting cells in the pancreas. The advance promises to improve diabetes research and cell-based therapies. Researchers led by ...
The currently approved islet-transplant method infuses islets into a vein in the liver. This invasive procedure requires the long-term use of immune-suppressing drugs to prevent islet rejection, ...
Pancreatic islet transplantation can cure diabetes but requires accessible, high-quality islets in sufficient quantities. Cryopreservation could solve islet supply chain challenges by enabling quality ...
A team of international scientists has made a major leap forward in diabetes research by successfully 3D printing functional human islets using a novel bioink (Monday, 30 June 2025, London, United ...
ProtoKinetix has announced the start of a phase 1 first-in-human clinical trial of AAGP PKX-001 treated islet cells used in conjunction with the Edmonton Protocol for the treatment of Type 1 diabetes.
Researchers have developed a method using engineered blood vessel cells (R-VECs) to improve islet transplantation which could offer a safer and more effective treatment for type 1 diabetes. In a study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results